Keyphrases
Diabetes
50%
Nephropathy
50%
Renal Endpoints
50%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
50%
Clinical Analysis
50%
Diabetic Kidney Disease
50%
Clinical Evaluation
50%
Renal Events
50%
Participatory Planning
50%
Evaluation Trial
50%
Meta-analysis
50%
Canagliflozin
50%
Atrial Fibrillation
50%
Flutter
37%
Hazard Ratio
31%
Objective Sleep Measures
25%
Subjective Sleep Measures
25%
Harvest Season
25%
Tekscan
25%
Balance Difficulty
25%
Hemorrhagic Stroke
18%
Cardiovascular Outcome Trials
18%
Causal Maps
16%
Engagement Research
16%
Patient Engagement in Research
16%
Stakeholder Approach
16%
Clear Effect
12%
Chronic Kidney Disease
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Placebo
12%
Ischemic Stroke
12%
Decreased Glomerular Filtration Rate
12%
Stroke Subtypes
12%
Estimated Glomerular Filtration Rate
12%
Doubling of Serum Creatinine
8%
Clinical Evaluation Study
8%
Overall Effect
6%
Fatal Stroke
6%
Inhibiting Effect
6%
Albuminuria
6%
Stroke Risk
6%
Random-effects Meta-analysis
6%
Nonfatal Stroke
6%
Medicine and Dentistry
Diabetes
100%
Canagliflozin
100%
Clinical Trial
100%
Nephropathy
100%
Diabetic Nephropathy
58%
Cardiovascular Effect
50%
Post-Hoc Analysis
50%
Sodium Glucose Cotransporter 2 Inhibitor
50%
Atrial Fibrillation
50%
Randomized Clinical Trial
50%
Apoplexy
50%
Meta-Analysis
50%
Cardiovascular System
19%
Hazard Ratio
19%
Glomerular Filtration Rate
15%
Placebo
11%
Cerebral Hemorrhage
11%
Renal Failure
8%
Evaluation Study
8%
Creatinine
8%
Brain Ischemia
7%
Chronic Kidney Disease
7%
Maturity Onset Diabetes of the Young
7%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Canagliflozin
100%
Kidney Disease
100%
Diabetic Nephropathy
58%
Randomized Clinical Trial
50%
Sodium Glucose Cotransporter 2 Inhibitor
50%
Atrial Fibrillation
50%
Brain Hemorrhage
18%
Placebo
16%
Non Insulin Dependent Diabetes Mellitus
12%
Brain Ischemia
12%
Chronic Kidney Failure
12%
Kidney Failure
8%
Creatinine
8%
Albuminuria
6%